News

Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac

PRINCETON, N.J.–(BUSINESS WIRE)– UPDATED Advaxis, Inc. (ADXS), a biotechnology company developing cancer immunotherapies, today published online a poster previously presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool that showed axalimogene filolisbac achieved durable response in a patient with persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC).

2017-06-27T11:55:32+00:00